Liver/Biliary Disorders News

WASHINGTON — In a Healio video exclusive, Saqr Alsakarneh, MD, MSc, describes “significant disparities” in race, ethnicity and sex among participants enrolled clinical trials for liver transplantation in the U.S.

WASHINGTON — Seladelpar use led to “rapid, marked and sustained improvement” in markers of cholestasis and liver injury among patients with primary biliary cholangitis, according to interim results of the ongoing, phase 3 ASSURE study.

Treatment with Bylvay resulted in a “significantly greater” change from baseline to week 24 in mean scratching scores and serum bile acids vs. placebo among pediatric patients with Alagille syndrome, according to ASSERT study results.

The FDA has declined to approve Dynavax’s supplemental biologics license application for the expanded use of its four-dose hepatitis B vaccine regimen in adult patients on hemodialysis, according to a manufacturer’s press release.

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.

NEW ORLEANS — In this video exclusive, Jonathan D. Leffert, MD, talks with Scott D. Isaacs, MD, FACP, FACE, and Sangeeta Kashyap, MD, about nomenclature for liver disease and how endocrinologists should approach screening and treatment.

In this exclusive Healio interview, Gideon Hirschfield, PhD, MB Bchir, the Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto, discusses the latest insights into the gut microbiome’s role as a key player in disease development and progression.

Low bone mineral density may be a risk factor for developing cirrhosis, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

Hepatocellular carcinoma screening in at-risk patients was linked to reduced mortality after accounting for lead-time and length-time biases, as well as improved early tumor detection and treatment, according to data in JAMA Network Open.

Facilitated telemedicine integrated into opioid treatment programs for patients with hepatitis C virus infection resulted in “substantially higher” cure rates compared with offsite referral to a hepatitis specialist, according to a study.